Asia Green Biotechnology Corp. Announces Grant of Application for Management Cease Trade Order
Asia Green Biotechnology Corp. Announces Grant of Application for Management Cease Trade Order
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES
不得在美國新聞線或在美國傳播
CALGARY, AB / ACCESSWIRE / May 8, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024 and April 26, 2024, the Alberta Securities Commission ("ASC") has granted the Company's application for the issuance of a Management Cease Trade Order ("MCTO").
亞洲綠色生物技術股份公司（"亞洲綠色"或"公司") (CSE:ASIA)宣佈，根據其於2024年4月17日和2024年4月26日發佈的新聞稿，阿爾伯塔證券委員會("ASC")已批准公司發出管理停止交易令（"MCTO"）的申請。
The MCTO prohibits the CEO and CFO of the Company from trading in the securities of the Company until such time as it has filed the following continuous disclosure documents (collectively, the "Documents"):
MCTO禁止公司的首席執行官和首席財務官在公司證券交易市場中交易，直到公司提交以下連續披露文件（"文件"）：
- the Company's Annual Audited Financial Statements for the year ended December 31, 2023, as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102"); and
- the Company's Management Discussion & Analysis for the year ended December 31, 2023, as required by section 5.1(2) of NI 51-102.
- CEO and CFO certificates relating to the Audited Annual Financial Statements, as required by NI 52-109.
- 公司年度審計財務報表，截至2023年12月31日，根據51-102國家工具4.2所要求的。持續披露義務；（“NI 51-102”）；
- 本公司2023年12月31日本管館討論和分析，根據NI 51-102的5.1(2)要求。
- 本公司根據NI 52-109的要求提交的與審計年度財務報表相關的CEO和CFO證書。
The Corporation is still working with its auditors and expects that the Documents will be filed by May 27, 2024, and that interim Q1 financial statements will be filed by May 30, 2024.
公司仍在與其核數師合作，預計將於2024年5月27日前提交文件，並在2024年5月30日前提交Q1季度財務報表。
During this period of default, the Company will continue to satisfy the provisions of the alternative information guidelines as required by National Policy 12-203 - Management Cease Trade Orders.
在此期間，公司將繼續滿足交替信息指南的規定，根據國家政策12-203所要求。管理層停止交易命令.
Asia Green confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments since the filing on November 29, 2023, of the Company's latest interim financial reports for the three-and-nine-month periods ended September 30, 2023.
亞洲綠色確認，除了在先前的新聞稿和重大變更報告中披露的信息外，在截至2023年9月30日的最新季度財務報告提交後，公司沒有發生任何重大業務發展。
For further information, contact:
如需更多信息，請聯繫：
Asia Green Biotechnology Corp.
David Pinkman (CEO)
T: 403 863-6034
E: david.pinkman@asiagreenbiotechnology.com
亞洲綠色生物技術股份有限公司。
大衛·平克曼 (CEO)
電話：403 863-6034
電子郵件：david.pinkman@asiagreenbiotechnology.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TSX創業公司交易所及其監管服務提供方（該術語定義在TSX創業公司政策中）不對此發佈的充分性或準確性承擔任何責任。
Caution Regarding Forward-Looking Information Forward-looking statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often, but not always, identified by words such as "believes", "may", "likely", "plans", or similar words. Forward- looking statements included in this news release include statements with respect to activities in Zimbabwe. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Corporation, including, but not limited to the impact of general economic conditions, industry conditions, currency fluctuations, and dependence upon regulatory approvals. The Corporation does not assume any obligation to update the forward-looking statements to reflect changes in assumptions or circumstances other than as required by applicable law.
關於前瞻性信息的注意事項前瞻性陳述-本新聞稿中所列出的某些信息可能包含具有重大已知和未知風險和不確定性的前瞻性陳述。這些前瞻性陳述經常但不總是被識別爲"相信"，"可能"，"可能"，"計劃"或類似詞語。本新聞稿所包含的前瞻性陳述包括與津巴布韋的活動有關的聲明。這些前瞻性陳述受到無數風險和不確定性的影響，其中某些風險和不確定性超出了公司的控制範圍，包括但不限於一般經濟狀況、行業狀況、貨幣波動和依賴於監管批准。公司不承擔更新前瞻性陳述以反映假設或情況變化的責任，除適用法律規定外。
SOURCE: Asia Green Biotechnology Corp.
資訊來源：亞洲綠色生物科技企業
譯文內容由第三人軟體翻譯。